Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 957

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9C
Chunk 957
---
 December 31, 

    2024  
    2023 
  
    Operating expenses: 

    Research and development expenses 
    $3,378  
    $90 
  
    General and administrative expenses 
     12,041  
     5,172 
  
    Total operating costs and expenses 
     15,419  
     5,262 
  
    Operating loss 
     (15,419) 
     (5,262)
  
    Other income (expenses): 

    Other income (expense), net 
     (890) 
     4,923 
  
    Interest income 
     13  
     15 
  
    Interest expense, net 
     (1,506) 
     (211)
  
    Total other (expense) income, net 
     (2,383) 
     4,727 
  
    Net income (loss) 
    $(17,802) 
    $(535)
  
    Less: Change in fair value and income impact of option liabilities 
     -  
     (5,521)
  
    Net income (loss) - diluted 
     (17,802) 
     (6,056)
  
    Basic earnings/(net loss) per share 
    $(20.53) 
    $(0.79)
  
    Diluted earnings/(net loss) per share 
    $(20.53) 
    $(8.92)
  
    Basic weighted-average common shares outstanding 
     867,096  
     669,739 
  
    Diluted weighted-average common shares outstanding 
     867,096  
     678,939 
  
    Comprehensive income (loss): 

    Foreign currency translation adjustment 
     3  
     (264)
  
    Total comprehensive income (loss) 
    $(17,799) 
    $(799)

The
accompanying notes are an integral part of these consolidated financial statements.

F-4

CONDUIT
PHARMACEUTICALS INC.

CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(in
thousands, except share amounts)

    Shares  
    Amount  
    capital  
    deficit  
    income  
    deficit 

    Common stock  
    Additional paid-in  
    Accumulated  
    Accumulated other comprehensive  
    Total stockholders’